Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI Germany (DAX) — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while iShares MSCI Germany (DAX) trades at $43.83. The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWG | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $44.56 |
52-Week Low | $205.48 | $38.08 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
EWG trades at $43.87 with no recent price change. Technical indicators show a bullish trend from moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. Recent news highlights European Central Bank policy decisions and German economic reforms influencing market sentiment.
The outlook is cautiously optimistic due to bullish technical signals, but limited fundamental data and overbought RSI levels pose risks. Investors should monitor European economic developments and company-specific financial updates for directional cues amid geopolitical and energy price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
